Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open, Multi-center and Single Arm Study Investigating Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Injection in Patients With Locally Advanced or Metastatic Melanoma and Standard Treatment Failure

NCT03013101 is registered in ClinicalTrials.gov with Shanghai Junshi Bioscience Co., Ltd. as lead sponsor.

NCT NCT03013101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03013101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open, Multi-center and Single Arm Study Investigating Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Injection in Patients With Locally Advanced or Metastatic Melanoma and Standard Treatment Failure
Lead sponsor
Shanghai Junshi Bioscience Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
December 28, 2016
Completion date
December 31, 2021
Enrollment
128 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma, metastatic melanoma